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Abstract
Background: Chronic lymphocytic leukemia is the most common form of leukemia in
adults. The prognostic impact of ZAP-70 in CLL has been reported in several studies.
The aim of conducting this study was to investigate the prevalence of ZAP-70 in
Sudanese patients with chronic lymphocytic leukemia attending Khartoum Oncology
Hospital.
Materials and Methods: A total of 93 newly diagnosed patients with chronic lym-
phocytic leukemia were enrolled in this study. Lymphadenopathy and organomegaly
were assessed in all participants using clinical examination, chest radiography, and
abdominal ultrasound. Full blood count was carried out by an automated hematology
analyzer. ZAP-70 was evaluated using flowcytometry on peripheral blood samples.
ZAP-70 was defined as positive expression at a cutoff level of 20%.
Results: There were 63 (67.7%) males and 30 (32.3%) females and the median age
of the group was 63 years; 68 patients (73.1%) were presented with anemia and 66
(70.9%) had lymphadenopath;y. Majority of our patients 35 (37.6%)were in Rai stage
IV. ZAP-70 positivity was detected in 21 patients (22.6%). There was no statistically
significant association of ZAP-70 with age, sex, lymphadenopathy, organomegaly,
hemoglobin concentration, total white blood cell count, platelet count and Rai staging
system (p-value > 0.05).
Conclusion: Only 21 patients (22.6%) were ZAP-70 positive. There was no association
between ZAP-70 and the study variables. Further studies to evaluate prognostic
role of ZAP-70 in Sudanese patients with chronic lymphocytic leukemia are
recommended.
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1. Introduction
Chronic lymphocytic leukemia (CLL) is characterized by a heterogeneous clinical course
[1] with survival times ranging frommonths to decades; this heterogeneity reflects the
biological diversity of CLL [2]. Neoplastic cells express Certain markers that can help
to predict the prognosis of patients with CLL [3, 4]. The detection of these markers
provides a vital tool that can stratify patients into groups with good or poor prognosis
[5].
The traditional prognostic parameters (clinical stage, pattern of bone marrow infil-
tration, lymphocyte doubling time, beta-2 microglobulin levels, and lactate dehydro-
genase level) are valuable but less accurate in prediction of disease progression [6, 7].
Last years, research in prognostic factors in CLL has focused on biological factors
such as the variable region of the immunoglobulin heavy chain gene (IgVH) mutational
status, CD38 and ZAP-70 expression. The strongest independent prognostic factor in
CLL is the presence of IgVH somatic mutations [8]. However, IgVH mutation studies
are not cost effective, technically demanding and are not available at most centers.
Therefore, there is a need for surrogate marker that is reliable, easily standardized and
more suitable for application in clinical laboratories [9].
The zeta-chain-associated protein kinase-70 (ZAP-70)was first described in 2003 [5]
and is present in normal T-cells, NK-cells, and not present in normal B-cells. Published
reports demonstrated a strong association between overexpression of ZAP-70 and
unmutated IGHV genes in CLL. Also, low expression of ZAP-70 is associated to mutated
IGHV genes [5, 10, 11] and time to disease progression and overall survival (OS) [5, 10–
13].
Although there has a consensus on the prognostic significance of ZAP-70, the
detection method of ZAP-70 at various laboratories has been a source of discussion
[14]. Several methods are used to study ZAP-70 expression in CLL but flowcytometry
remains the most suitable, reliable and applicable method into routine use [10].
Crespo et al. [15] and Rassenti et al. [11] demonstrated that patients with more than
20% ZAP-70 positive cells have higher risk of disease progression and lower survival
rates compared with those with less than 20% ZAP-70-positive cells, suggesting that
ZAP-70 might be more indicative of worse prognosis compared with the mutational
status of the IGHV.
In this study, the authors aimed to determine the frequency of ZAP-70 among
Sudanese patients with chronic lymphocytic leukaemia and to associate ZAP-70
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expression to age, sex, lymphadenopathy, organomegaly, haemoglobin concentration,
TWBCs count, platelet count, and modified Rai clinical staging system.
2. Materials and Methods
2.1. Patients
A total of 93(69.7% males and 30.3% females) newly diagnosed (based on CBC and
immunophenotyping), untreated B-CLL patients, attending the Khartoum Oncology
Hospital during the period from September 2016 to February 2017, were enrolled in
this cross-sectional study. Patients were diagnosed as CLL, in accordance with the
International CLL Workshop Criteria [16] and the Guidelines for the diagnosis and
treatment of chronic lymphocytic leukemia [17]. Also, all the patients were staged
according to the Rai staging system [18]; 3 ml of peripheral blood (PB) was collected
in EDTA tubes from each patient according to the standard protocol. The PB samples
were processed within 6–24 h of collection, preserved at room temperature (22–24ºC).
Clinical and demographic data were collected in a predesigned questionnaire. This
study was approved by the ethical committee of the Sudan Medical Specialty Board
(SMSB) and an informed consent was obtained from all patients before sampling in
accordance to the guidelines and requirements of the ethical committee.
3. Methods
3.1. Clinical examination
Each patient was subjected to a history taking and physical examination that was
performed to determine the diameters of lymph nodes. Chest X-ray and abdominal
ultrasound were used to evaluate the size of the liver and spleen.
3.2. Complete Blood Count (CBC)
CBC was carried out using automated cell counter (Sysmex XE-2100𝑇𝑀).
3.3. Immunophenotyping (IPT)
IPT was carried out to confirm the diagnosis of CLL using the following monoclonal
antibodies (Mo Ab) (Beckman Coulter); CD45, CD5, CD19, CD20, CD22, CD23, kappa and
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lambda light chains, FMC7, CD79b. A marker was considered positive at a cutoff level
of 20%.
3.4. Flowcytometric analysis of intracellular ZAP-70 expression
Four color flowcytometer (COULTER EPICS XL-MCLTM Flowcytometer – Miami, Florida
– USA) with SYSTEM II software was used to detect and measure the intracellular
ZAP70 expression in PB samples according to the following protocol; First PerFix-nc
a fixation and permeabilization kit was used as follows: Pipette 50 μL of blood sample
into the bottom of each appropriately labeled tube. Add 5 μL of the FixativeReagent to
each tube. Vortex immediately and incubate for 15 min at room temperature (18–25∘C).
Vortex the fixed specimen again and add 300 μL of the Permeabilizing Reagent to each
tube; vortex immediately. Then, immediately add to each tube 20 μl ZAP-70 Isoclonic
Control. Vortex immediately and incubate for 10 min at room temperature (18–25∘C).
Add to each tube 20 μL ZAP-70-PE (PN B57658). Vortex immediately and incubate for
45 min at room temperature protected from light. Add 3 mL of the Final 1 X Reagent
(prepared from the 10 X concentrated Final Solution) to each tube; vortex immediately.
Pellet the cells at 500 x g for 5 minutes, and completely discard the supernatant by
aspiration. Re-suspend the cell pellet in 0.5 mL of the same Final 1X Reagent; the
sample is now ready for acquisition on a flowcytometer. The ZAP-70 expression was
considered positive at a cutoff level of 20%.
3.5. Data analysis
The collected data were analyzed using the software program of the Statistical Pack-
age for Social science for Windows (SPSS), version 19. Quantitative variables were
summarized as mean and median and qualitative variables as percentage. Categorical
variables were analyzed using Chi-Square test. P value less than 0.05 was defined as
significant.
3.6. Results
A total of 93 CLL patients (63 (67.7%) males and 30 (32.3%) females) were involved
in this study with a mean (± SD) age 62.29 ± 11.68, median 63 years (range: 36–95).
According to Rai staging system, 35 (37.6%) patients were in Stage IV, 28 (30.1%)
patients were in Stage III, 17 (18.3%) patients were Stage II, 9 (9.7%) patients were
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in Stage I, 4 (4.3%) patients were Stage 0; 66 (71.0%) patients presented with lym-
phadenopathy, 50 (53.8%) with splenomegaly, 23 (24.7%) with hepatomegaly. Ane-
mia was detected in 68 (73.1%) patients and thrombocytopenia in 42 (45.2%) patients
(Table 1). Immunophenotyping results revealed characteristic CLL immunophenotype.
We found that themean (±SD) expression of ZAP70was 17.06± 21.89, with amedian
of 8.3 (range: 0.03–85.5%). Out of 93 patients, only 21 (22.6%) patients were positive
for ZAP70 expressions at cutoff levels of 20%, whereas 72 (77.4%) patients were neg-
ative. No significant association was observed between ZAP70 expressions at cutoff
levels of 20% and the study variables (Age, Sex, Lymphadenopathy, organomegaly,
Hb concentration, TWBCs count, Platelets count, and Rai staging system) (p-value >
0.05) (Table 2).
T 1: Demographic, clinical and laboratory characteristics of patients.
Parameter Frequency No. (%) Parameter Frequency No. (%)
Age Hemoglobin (g/dl)
Mean ± SD 62.29 ± 11.68 Low 68 (73.1%)
Median (range) 63 (36–95) Normal 25 (26.9%)
≥ 60 61 (65.6%) Leukocyte count (×109/L)
< 60 32 (34.4%) < 50 27 (29.0%)
Sex ≥ 50 66 (71.0%)
Male: Female Ratio 1:0.48 Platelets count (×109/L)
Male 63 (67.7%) < 150 42 (45.2%)
Female 30 (32.3%) ≥ 150 51 (54.8%)
Lymphadenopathy Rai staging system
Present 66 (71.0%) Stage 0 4 (4.3%)
Absent 27 (29.0%) Stage I 9 (9.7%)
Splenomegaly Stage II 17 (18.3%)
Present 50 (53.8%) Stage III 28 (30.1%)
Absent 43 (46.2%) Stage IV 35(37.6%)
Hepatomegaly ZAP-70 Expression
Present 23 (24.7%) Positive 21 (22.6%)
Absent 70 (75.3%) Negative 72 (77.4%)
4. Discussion
ZAP-70 has a great future as a prognostic marker as it has been found that ZAP-70
is highly predictive of time to treatment in a large cohort of early-stage (Rai 0-1) and
untreated CLL [11, 19]. The optimal cutoff for ZAP-70 positivity was defined by many
authors as 20% [10, 12, 20, 21]. We found that 21 (22.6%) patients were positive for
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T 2: Association of ZAP-70 expression with the study variables.
Variables Zap-70 Frequency No. (%) P-value
ZAP-70 positive ZAP-70 negative
Age
≥ 60 11 (52.4%) 50 (69.4%) 0.15
< 60 10 (47.6%) 22 (30.6%)
Sex
Male 14 (15.1%) 49 (52.7%) 0.91
Female 7 (7.5%) 23 (24.7%)
Lymphadenopathy
Present 15 (16.1%) 51 (54.8%) 0.96
Absent 6 (6.5%) 21 (22.6%)
Splenomegaly
Present 12 (12.9%) 38 (40.9%) 0.83
Absent 9 (9.7%) 34 (36.5%)
Hepatomegaly
Present 5 (5.4%) 18 (19.4%) 0.85
Absent 16 (17.2%) 54 (58.0%)
Hemoglobin concentration (g/dl)
Low 15 (16.1%) 53 (57.0%) 0.84
Normal 6 (6.5%) 19 (20.4%)
TWBCs count ×109
< 50 5 (5.4%) 22 (23.7%) 0.55
≥ 50 16 (17.2%) 50 (53.7%)
Platelet count ×109
< 150 9 (9.7%) 33 (35.5%) 0.81
≥ 150 12 (12.9%) 39 (41.9%)
Rai staging system
Stage 0 1 (1.1%) 3 (3.2%) 0.88
Stage I 1 (1.1%) 8 (8.6%)
Stage II 3 (3.2%) 14 (15.1%)
Stage III 7 (7.5%) 21 (22.6%)
Stage IV 9 (9.6%) 26 (28.0%)
ZAP70 expressions at cutoff levels of 20% and 72 (77.4%) patients were negative.
Many published reports indicated ZAP-70 positivity in CLL ranging from 25% to 57%
as presented in Table 3; our result is slightly lower.
Our results revealed that there was no significant association of ZAP-70 with
age, sex, lymphadenopathy, organomegaly, hemoglobin concentration, TWBCs count,
Platelets count, and Rai staging system (p > 0.05). Our findings go in line with a study
done by Gogia et al. from India who reported no association of ZAP-70 positivity with
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age, sex, lymphadenopathy, organomegaly, and Rai staging system [9]. A study by
Del Poeta et al. and Hus et al. indicated a significant correlation between high ZAP-70
levels and advanced Rai stage and splenomegaly [20 22]. This is in disagreement with
our results. On the other hand, El-Kinawy et al. reported that ZAP-70 expression was
significantly associated with advanced Rai stages 3 and 4, while it was negatively
correlated to Hb levels and platelet counts [23].
Crespo et al. [10] found that at a cutoff of 20%, ZAP70 positivity clearly separated
CLL patients into two groups; those with < 20% ZAP70 had increased survival time
and decreased chance of disease progression.
In most laboratories, ZAP70 is considered positive when at least 20% of the CLL-cells
have a signal that is greater than the background control signal. Subjectivity in these
methods can lead to variable results among research laboratories. To overcome this
subjectivity, it has been suggested that mean fluorescence intensity (MFI) values from
CLL-cells and background T lymphocytes should be measured rather than calculating
the percentage of positive cells [24]. Rossi et al [24] reported that when using MFI
values and calculating the ratio of T-cells to B-cells, those patients with a ratio lower
than 3 had a shorter time-to-treatment than ZAP70-negative CLL patients and those
estimated to be ZAP70-positive by the T-cell percentage method only [25].
Unfortunately, prognostic impact of ZAP70 could not be investigated in our study
due to lack of follow-up.
Contrast of our results with other workers may be contributed to by many factors
such as biology of disease in the Sudanese population, sample sizes, and sensitivity of
method.
T 3: Comparison of ZAP 70 with literature.
Study Year No. of Patients ZAP 70%
Crespo et al. [10] 2003 56 57
Schoroer et al. [26] 2005 252 46
Hus et al. [24] 2006 156 36
D’Arena et al. [21] 2007 157 36
Gogia et al. [9] 2013 80 25
Present study 2017 93 22.6
5. Conclusion
The present study was aimed to study the prevalence of ZAP-70 in CLL patients and
to relate them to the study variables (age, sex, lymphadenopathy, organomegaly,
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hemoglobin concentration, TWBCs count, Platelets count, and Rai staging system).
ZAP-70 positivity was detected in 21 patients (22.6%). There was higher frequency
of high-risk group among study population. There was no significant association of
ZAP-70 positivity with the study variables. The prognostic value of ZAP-70 should
be tested in the setting of a controlled prospective trial. Further studies are strongly
recommended to develop a standardized flowcytometry protocol using MFI and T/B
ratio method to verify the prognostic impact of ZAP70.
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